| Psoriasis vulgaris
Skyrizi vs Duobrii
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Skyrizi vs Duobrii with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDuobrii has a higher rate of injection site reactions vs Skyrizi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Duobrii but not Skyrizi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Skyrizi
Duobrii
At A Glance
SC injection
Every 8-12 weeks
IL-23 antagonist
Topical
Once daily
Corticosteroid/retinoid combination
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter.
Crohn Disease Induction: 600 mg IV infusion over at least 1 hour at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Ulcerative Colitis Induction: 1,200 mg IV infusion over at least 2 hours at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Psoriasis vulgaris Apply a thin layer once daily to affected areas, rubbing in gently; total dosage should not exceed approximately 50 g per week; avoid application on the face, groin, or axillae; do not use with occlusive dressings unless directed by a physician; discontinue when control is achieved.
Contraindications
- Previous serious hypersensitivity reaction to risankizumab-rzaa or any excipient
- Pregnancy
Adverse Reactions
Most common Upper respiratory infections, headache, fatigue, injection site reactions, tinea infections, arthralgia, pyrexia, rash
Serious Cellulitis, osteomyelitis, sepsis, herpes zoster, pneumonia
Postmarketing Eczema, rash
Most common (>=1%) contact dermatitis, application site pain, folliculitis, skin atrophy, excoriation, rash, skin abrasion, skin exfoliation
Pharmacology
Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine, inhibiting its interaction with the IL-23 receptor and suppressing the release of pro-inflammatory cytokines and chemokines.
Combination of halobetasol propionate, a synthetic corticosteroid that modulates cellular signaling, immune function, and inflammation, and tazarotene, a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds RAR-beta and RAR-gamma receptors to modify gene expression; precise mechanisms in plaque psoriasis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Skyrizi
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Duobrii
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Skyrizi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Duobrii
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Skyrizi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Duobrii
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Duobrii.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SkyriziView full Skyrizi profile
DuobriiView full Duobrii profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.